Mark Ennis Ketner

Title: Innovations by Inventor Mark Ennis Ketner

Introduction: Mark Ennis Ketner, an accomplished inventor based in Apex, NC, holds two patents related to innovative drug delivery systems. His work primarily focuses on the development of dry powder inhalers that enhance the efficiency of pharmaceutical formulations for inhalation purposes.

Latest Patents: Mark's latest patents include groundbreaking advancements in dry powder inhalers. One of his patents details a multi-dose dry powder package designed for dispensing pharmaceutical grade formulations of inhalable dry powder. This invention features a blister package comprising a series of sealed blisters, each containing a dry powder within a defined channel. The innovative design also incorporates a movable blade cartridge that precisely opens the blister, and an extendable mouthpiece for user convenience. The operational mechanism allows a user to manipulate the mouthpiece to position the blister correctly and activate the blade across the blister ceiling to dispense the powder effectively.

Additionally, Mark has developed blister packages that utilize a piezoelectric active layer. This feature facilitates the active dispersion of dry powder by flexing to vibrate, thereby improving drug containment systems significantly.

Career Highlights: Mark is currently associated with Oriel Therapeutics, Inc., where he contributes his expertise in inhalation technology. His inventive solutions aim to simplify drug delivery and ensure better patient compliance in medical treatments.

Collaborations: Throughout his career, Mark has had the opportunity to work alongside esteemed colleagues Anthony James Hickey and Timothy M. Crowder. Their collaborative efforts have undoubtedly played a vital role in advancing the field of inhalation therapy.

Conclusion: Mark Ennis Ketner stands out as an innovative inventor whose contributions reflect the potential of modern medicine to enhance drug delivery methods. With his patents, he is at the forefront of improving pharmaceutical practices, ultimately benefiting patients who rely on inhalable medications. His ongoing dedication to innovation and collaboration holds promise for future advancements in this crucial area of health care.